Overview
Personalis provides advanced genomic sequencing and analysis services for precision oncology, including the ACE Technology platform to interrogate difficult genome regions and ImmunoID NeXT for multidimensional tumor profiling. They offer NeXT Personal, an ultra-sensitive liquid biopsy assay for minimal residual disease (MRD) detection using whole genome sequencing on FFPE tissue. Personalis operates an on-site CAP-accredited clinical lab to support biopharma in developing next-generation cancer therapies and diagnostics.
Frequently asked questions
- What genomic technologies does Personalis offer for oncology R&D?
- Personalis offers ACE Technology for interrogating difficult genome regions, ImmunoID NeXT for multidimensional tumor sequencing, and NeXT Personal liquid biopsy for high-sensitivity MRD detection tracking 1800 variants.
- Does Personalis have regulatory accreditations for clinical testing?
- Yes, Personalis operates an on-site CAP-accredited clinical genomics lab to support precision oncology diagnostics and therapies.
- What services support biopharma in cancer therapy development?
- Personalis provides neoantigen identification for cancer vaccines, comprehensive tumor profiling, and liquid biopsy assays to advance precision oncology from R&D to commercialization.